Alnylam Pharmaceuticals

ALNY · NASDAQ

$230.71−$2.58 (−1.11%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $233.29

Latest news

Press releaseOct 15, 8:00 AM ETBusiness Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
NewsOct 5, 3:00 PM ETPiero Cingari
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
Press releaseOct 5, 11:00 AM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Press releaseOct 5, 9:00 AM ETGlobe Newswire
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Press releaseOct 2, 5:40 PM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
NewsOct 1, 12:29 PM ETPiero Cingari
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Press releaseSep 29, 9:00 AM ETBusiness Wire
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Press releaseSep 2, 8:00 AM ETBusiness Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Press releaseAug 30, 8:23 AM ETBusiness Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Press releaseAug 26, 8:00 PM ETGlobe Newswire
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.
Press releaseAug 24, 8:33 AM ETBusiness Wire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Press releaseAug 22, 4:00 PM ETPRNewswire
(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm
Press releaseAug 21, 9:05 AM ETGlobe Newswire
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Press releaseAug 20, 2:50 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
NewsAug 20, 12:03 PM ETErica Kollmann
Biotech Is Booming, But These 2 Stocks Missed the Memo
Press releaseAug 20, 9:00 AM ETGlobe Newswire
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Press releaseAug 19, 8:00 PM ETBusiness Wire
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Press releaseAug 19, 5:53 PM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Press releaseAug 16, 4:58 PM ETPRNewswire
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Press releaseAug 15, 10:25 AM ETGlobe Newswire
Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Press releaseAug 14, 6:24 PM ETBusiness Wire
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Press releaseAug 13, 11:00 AM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Press releaseAug 12, 1:55 PM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Press releaseAug 4, 7:25 PM ETGlobe Newswire
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Press releaseAug 4, 11:10 AM ETGlobe Newswire
Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Press releaseAug 3, 7:34 PM ETGlobe Newswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Press releaseAug 3, 6:20 PM ETBusiness Wire
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Press releaseJul 31, 6:54 PM ETGlobe Newswire
ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NewsJul 30, 2:37 PM ETVandana Singh
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
NewsJul 30, 1:29 PM ETPiero Cingari
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
NewsJul 30, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsJul 30, 12:02 PM ETAvi Kapoor
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
NewsJul 30, 8:01 AM ET
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate
Press releaseJul 30, 8:00 AM ETBusiness Wire
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Press releaseJul 15, 3:30 AM ETBusiness Wire
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Press releaseJun 12, 9:00 AM ETBusiness Wire
Alnylam to Host Tenth "RNAi Roundtable" Webcast Series
NewsJun 3, 4:47 PM ET
Alnylam Pharma And Inceptive Nucleics Announce $2B Collaboration Agreement With Upfront Consideration Of $30M, Including Cash And Purchase Of Inceptive Equity
Press releaseJun 3, 4:45 PM ETBusiness Wire
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Press releaseMay 28, 9:15 AM ETPRNewswire
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
Press releaseMay 19, 8:30 AM ETBusiness Wire
Alnylam Issues 2025 Corporate Responsibility Report
NewsApr 30, 8:01 AM ET
Alnylam Pharmaceuticals Q1 Adj. EPS $1.99 Beats $0.93 Estimate, Sales $1.167B Beat $1.114B Estimate
NewsApr 30, 7:11 AM ET
Earnings Scheduled For April 30, 2026

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Biotech Is Booming, But These 2 Stocks Missed the Memo

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%

12 Health Care Stocks Moving In Thursday's Intraday Session

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam to Host Tenth "RNAi Roundtable" Webcast Series

Alnylam Pharma And Inceptive Nucleics Announce $2B Collaboration Agreement With Upfront Consideration Of $30M, Including Cash And Purchase Of Inceptive Equity

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

Alnylam Issues 2025 Corporate Responsibility Report

Alnylam Pharmaceuticals Q1 Adj. EPS $1.99 Beats $0.93 Estimate, Sales $1.167B Beat $1.114B Estimate

Earnings Scheduled For April 30, 2026